Drawing on 25 years of successful experience in the academic, entrepreneurial, and Fortune 500 worlds (exclusively focused on biotechnology), Bill brings an unusual combination of both business acumen and scientific expertise to our clients' aid, enabling us to work productively where few others can, across the typical divide between R&D and marketing/business development. This is Busa Consulting's unique value proposition.
Bill's entrepreneurial experience dates back to the 1990s, beginning at the biotech tools start-up, Cellomics Inc., where he served as Vice President and Chief Scientific Officer. There he led multiple teams bringing to market the first high-content screening (automated high-throughput fluorescence microscopy) instrumentation, software, and reagent systems for cell-based drug discovery -- a technology which has, since its introduction by Cellomics, become a mainstay of modern pharmaceutical R&D. His other responsibilities included identification and management of external strategic relationships, work with the Board and prospective investors, and close collaboration with Sales to present the technology to pharmaceutical thought-leaders. Bill's tenure at Cellomics spanned its growth from a pre-revenue start-up to a successful operating company of 200+ FTEs. Cellomics was acquired by Thermo Fisher Scientific, and remains today the leading name in high-content screening instrumentation.
Bill's subsequent Fortune 500 experience culminated at BD Technologies (Becton, Dickinson and Co.'s worldwide R&D headquarters) where he architected BD's 'cell therapy enablement' business strategy and built and led its Cell & Tissue Technologies unit, a 40+ FTE team of biologists, chemists, engineers, information technologists and business development professionals acquiring, developing and commercializing new technologies for cell therapy, cell analysis, diagnostics and clinical specimen preservation. The team's achievements included the development of automated high-throughput combinatorial screening for the 'industrialization' of cell biological R&D, commercialization of BD's highly multiplexed (200+ markers in parallel) flow cytometry technology for drug discovery and cell therapy (BD FACS™CAP), and the acquisition and/or development of the first cutting-edge products in BD's new cell therapy enablement product line, including BD Mosaic™ Mesenchymal Stem Cell Culture Environment and BD SMC4 reagent for efficient induced pluripotent stem cell (iPSC) expansion and reprogramming.
In 2002, responding to several requests for assistance with early-stage biotechnology companies, Bill founded Busa Consulting. Since then BCL has served more than 20 organizations, from virtual start-ups to large publicly-traded corporations, plus several not-for-profit organizations. Our clients span the globe, from Asia, the Middle East, Europe, and Canada, to both U.S. coasts.
Dr. Busa holds a Ph.D. (Univ. of California, Davis) and a B.S. (University of California, Irvine) in Biological Sciences. He is an elected Fellow of the American Association for the Advancement of Science (AAAS) and an elected Member of the Marine Biological Laboratory, Woods Hole. Prior to his business career he served for over ten years as a professor of both biology and biophysics at The Johns Hopkins University, where his team's NIH-funded research in signal transduction mechanisms was published in such leading journals as Science, Cell, PNAS, Development, and the Journal of Cell Biology. Dr. Busa has served on the boards of several companies, National Institutes of Health advisory committees, and has been an advisor to state economic development organizations.Next: Why Busa Consulting?